all report title image
  • Published On : Aug 2022
  • Code : CMI1134
  • Industry : Pharmaceutical
  • Pages : 215
  • Formats :

Intravenous solutions (IV) are administered in patients to provide sugar, salt and water directly into venous circulation. IV solutions and electrolytes are used for fluid resuscitation, routine maintenance, replacement, and redistribution. Nowadays, intravenous drugs, nutrition and mixed solutions have become an integral part of modern therapy. The intravenous route of administration is commonly used for rehydration or to provide nutrients for those who cannot, or will not, due to reduced mental states or otherwise, consume food or water by mouth. It may also be used to administer medications or other medical therapy such as blood products or electrolytes to correct electrolyte imbalances.

Global intravenous solutions market size was valued at US$ 9,907.8 Million in 2022 and is expected to witness a CAGR of 6.1% over the forecast period (2022 – 2030).

Figure 1. Global Intravenous Solutions Market Share (%), by Solution Type, 2022

Intravenous Solutions  | Coherent Market Insights

Increasing launches and regulatory approvals for intravenous solution injection is expected to drive growth of the global intravenous solution market

Market players are involved in launching new intravenous injection solutions which is expected to boost the growth of global intravenous solutions market over the forecast period. For instance, in September 2021, Baxter International Inc., a global sterile medication production company, announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine). Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure). Baxter’s formulation of norepinephrine is the first and only manufacturer-prepared ready-to-use formulation and is available in 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) strengths.

CMI table icon

Intravenous Solutions Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 9,907.8 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 6.1% 2030 Value Projection: US$ 15,906.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Solution type: Saline (Normal Saline (0.9% NaCl) , Hypertonic Saline), Lactated Ringer’s, Amino Acid, Vitamins & Minerals, Heparin and Trace Elements, Mixed Solutions
  • By Bag type: Large Volume Bags (greater than 250ml), Small Volume Bags (less than 250ml)
  • By Application: Basic IV Solution, Nutritional IV Solution, Blood IV Solution, Drug IV Solution, Irrigation IV Solution
  • By End User: Hospitals, Clinics, Ambulatory Surgery Centers, Home Care Settings
Companies covered:

Baxter International Inc., ICU Medical. Inc, B. Braun Melsungen Ag, Grifols, S.A., Fresenius Kabi USA, LLC, Vifor Pharma Management Ltd, JW Life Science, Amanta Healthcare, Axa Parenterals Ltd, and Salius Pharma Private Limited, Pfizer, Inc, Otsuka Pharmaceutical Co., Ltd, Ajinomoto Co., Inc., B. Braun Melsungen AG, Soxa Formulations & Research Pvt.Ltd, Sichuan Kelun Pharmaceutical Co Ltd.

Growth Drivers:
  • Increasing launches and regulatory approvals for intravenous solution injection
  • Increasing launches of parenteral (intravenous) nutrition (PN) products
Restraints & Challenges:
  • Increasing recalls of intravenous products

Figure 2. Intravenous Solutions Market Share (%), by Region, 2022

Intravenous Solutions  | Coherent Market Insights

Increasing launches of parenteral (intravenous) nutrition (PN) products by key market players is attributing to the highest share of North America market in the global intravenous solutions market.

Increasing launches of parenteral (intravenous) nutrition (PN) products by key players in market for developing global intravenous solutions is expected to drive market growth over the forecast period. For instance, in June 2019, Eurolife Healthcare, a manufacturer and distributor of specialty infusion & pharmaceuticals, launched two intravenous IV products: Discport and Lifeport in the India drug market. The product is considered as smart intravenous infusion, which encompasses the latest technology that reduces the chances of any infection.

Global Intravenous Solutions Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

The sudden outbreak of COVID-19 has bought the world to a standstill. The demand for IV solutions has increased due to the fast spread of coronavirus illness (COVID-19), which will allow patients in intensive care units to receive vital nutrients (ICU). In addition to this, a significant growth-inducing element is the rise in diabetes, cancer, gastrointestinal problems, and neurological illnesses. Additionally, IV solution therapy's superior efficacy and quicker response time are fostering market expansion. It is employed to treat chronic dehydration, a disease that can lead to weariness, memory loss, irritability, and other health issues. For instance, in February 2022, the World Health Organization published a report which stated that nearly 10 million deaths in 2020, or nearly one in six deaths globally due to cancer. Cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries like India and Bangladesh.

Thus, impact of the Coronavirus (COVID-19) pandemic has driven growth of the global intravenous solutions market during the forecast period.

Global Intravenous Solutions Market: Key Developments

  • In December 2020, Royal Philips, a health technology company, announced that it signed an agreement to acquire Vesper Medical Inc., a U.S.-based medical technology company that develops minimally-invasive peripheral vascular devices. Vesper Medical will further expand Philips portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease. The transaction, which is subject to customary closing conditions.
  • For instance, in June 2022, Breckenridge Pharmaceutical, Inc., a manufacturing company, announces that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Cabazitaxel Intravenous Powder. This product was developed in collaboration with Natco Pharma Limited, a multinational pharmaceutical company, Breckenridge received final approval for the 60mg/1.5mL (40mg/mL) strength.   According to industry sales data, Jevtana Kit generated annual sales of US$ 303 million during the twelve months ending May 2022.

Intravenous Solutions Market Restraints

Growth of the global intravenous solution market is expected to be hampered over the forecast period, owing to increasing FDA recalls of IV products. For instance, in August 2018, the U.S. FDA recalled Becton Dickinson & Company’s NEXIVA Closed IV Catheter System Dual Port 18GA 1.25 IN (BD Nexiva catheter) due to failure in the needle tip shield/safety mechanism.

Key Players

Key players operating in the global intravenous solutions market include Baxter International Inc., ICU Medical. Inc, B. Braun Melsungen Ag, Grifols, S.A., Fresenius Kabi USA, LLC, Vifor Pharma Management Ltd, JW Life Science, Amanta Healthcare, Axa Parenterals Ltd, and Salius Pharma Private Limited, Pfizer, Inc, Otsuka Pharmaceutical Co., Ltd, Ajinomoto Co., Inc., B. Braun Melsungen AG, Soxa Formulations & Research Pvt.Ltd, Sichuan Kelun Pharmaceutical Co Ltd.

Intravenous solutions are fluids, which are administrated to a patient directly into the venous circulation. These fluids are sterile, non-pyrogenic solutions used for fluid replenishment and caloric supply in single dose container for intravenous administration. There are various types of intravenous solutions available in the market such as sodium chloride, lactated ringers, dextrose in water, and others. Intravenous therapy is ideal for patients suffering from nutritional deficiency and dehydration. Dehydration can contribute to various affects such as

  • Balance of important minerals (electrolytes) in the body.
  • Cognitive (mental) performance.
  • Energy level.
  • Gastrointestinal function (your ability to digest food and create pee and poop).
  • Headache frequency and intensity.
  • Physical performance.
  • Skin health.

Market Dynamics

Increasing prevalence of diarrhoea is expected to boost the global intravenous solution market growth over the forecast period. For instance, in July 2022, UNICEF (United Nations International Children's Emergency Fund), an agency of the United Nations responsible for providing humanitarian and developmental aid to children worldwide, published a report which accounted for 9 per cent of all deaths among children under age 5 worldwide in 2019 due to Diarrhoea, whereas over 1,300 young children dying each day, or about 484,000 children a year globally due to diarrhoea.

Moreover, according to an article published in the Lancet Infectious Diseases, September 2018, diarrhoea was the third leading cause of disability-adjusted life year (DALYs) in 2016, which accounted for 74.4 million DALYs, globally. According to the same source, diarrhoea was the eighth leading cause of death, which accounted for 1,655,944 deaths in 2016 globally.

Key features of the study:                                         

  • This report provides an in-depth analysis of the global intravenous solutions market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 – 2030, considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global intravenous solutions market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, Baxter International Inc. ICU Medical, Inc, B. Braun Melsungen Ag, Grifols, S.A., Fresenius Kabi USA, LLC, Vifor Pharma Management Ltd, JW Life Science, Amanta Healthcare, Axa Parenterals Ltd, and Salius Pharma Private Limited, Pfizer, Inc, Otsuka Pharmaceutical Co., Ltd, Ajinomoto Co., Inc., B. Braun Melsungen AG, Soxa Formulations & Research Pvt.Ltd, Sichuan Kelun Pharmaceutical Co Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global intravenous solutions market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global intravenous solutions market.

Detailed Segmentation:

  • Global Intravenous Solutions Market, By Solution type:
    • Saline
      • Normal Saline (0.9% NaCl)
      • Hypertonic Saline
    • Dextran
    • Lactated Ringer’s
    • Amino Acid
    • Vitamins & Minerals
    • Heparin and Trace Elements
    • Mixed Solutions
  • Global Intravenous Solutions Market, By Bag type:
    • Large Volume Bags (greater than 250ml)
    • Small Volume Bags (less than 250ml)
  • Global Intravenous Solutions Market, By Application:
    • Basic IV Solution
    • Nutritional IV Solution
    • Blood IV Solution
    • Drug IV Solution
    • Irrigation IV Solution
  • Global Intravenous Solutions Market, By End User:
    • Hospitals
    • Clinics
    • Ambulatory Surgery Centers
    • Home Care Settings
  • Global Intravenous Solutions Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country 
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country 
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Country 
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Baxter International Inc.*
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • ICU Medical, Inc.
    • Braun Melsungen Ag
    • Grifols, S.A.
    • Fresenius Kabi USA, LLC
    • Vifor Pharma Management Ltd.
    • JW Life Science
    • Amanta Healthcare
    • Axa Parenterals Ltd.
    • Salius Pharma Private Limited.
    • Pfizer, Inc.
    • Otsuka Pharmaceutical Co., Ltd
    • Ajinomoto Co., Inc.
    • Braun Melsungen AG
    • Soxa Formulations & Research Pvt.Ltd
    • Sichuan Kelun Pharmaceutical Co Ltd

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global intravenous solutions market is estimated to surpass US$ 15,906.0 Million by 2030
Major players operating in the market include Baxter International Inc., ICU Medical. Inc, B. Braun Melsungen Ag, Grifols, S.A., Fresenius Kabi USA, LLC, Vifor Pharma Management Ltd, JW Life Science, Amanta Healthcare, Axa Parenterals Ltd, and Salius Pharma Private Limited, Pfizer, Inc, Otsuka Pharmaceutical Co., Ltd, Ajinomoto Co., Inc., B. Braun Melsungen AG, Soxa Formulations & Research Pvt.Ltd, Sichuan Kelun Pharmaceutical Co Ltd.
Among solution type, Lactated Ringer segment generated significant revenue in 2022, owing to increasing approval by the key market players.
Increasing launches and regulatory approvals for intravenous solution injection is expected to drive growth of the market.
The market is estimated to exhibit a CAGR of 6.1% over the forecast period.
Among regions, North America is expected to witness significant growth over the forecast period, owing to increasing launches of parenteral (intravenous) nutrition (PN) products.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo